Waldenström Macroglobulinemia

Waldenström macroglobulinemia develops because of genetic changes in abnormal B cells. These cells change into lymphoplasmacytic cells and produce more monoclonal IgM. In many cases, a MYD88 mutation can be found. However, this mutation does not fully explain why the disease develops. It is part of the disease process.

The disease cannot always be traced back to clear causes. Still, some risk factors are linked more often with Waldenström macroglobulinemia. These include:

• Older age
• Male sex
• Genetic predisposition and family history
• IgM monoclonal gammopathy of undetermined significance as a possible precursor
• Certain autoimmune diseases and chronic inflammatory processes

IgM MGUS is an important risk factor. It is a monoclonal gammopathy of the IgM type. It is also one of the best known precursors of Waldenström macroglobulinemia. People with IgM MGUS have a higher risk of developing Waldenström macroglobulinemia or a related B cell disease over time. Studies also show that first degree relatives of affected people have a higher risk of Waldenström macroglobulinemia, other B cell lymphomas, and MGUS. This suggests that genetic factors play an important role.

Even if these risk factors are present, this does not mean that Waldenström macroglobulinemia will develop. In most cases, no clear trigger can be found. A precise diagnosis is much more important. It forms the basis for treatment planning and prognosis.

The symptoms of Waldenström macroglobulinemia can vary. They are not only caused by the growth of lymphoplasmacytic cells in the bone marrow. They can also result from the IgM paraprotein these cells produce. At first, there may be no symptoms. Symptoms may only increase later as the disease progresses.

It is typical for symptoms to develop slowly. At the beginning, they may seem quite unspecific. Later, anemia, enlarged lymph nodes, or problems caused by increased blood viscosity may occur. Most symptoms develop because normal blood formation is displaced. They can also result from IgM deposits in blood vessels and nerves. Organ involvement may occur if lymph nodes, the spleen, or the liver become enlarged.

Symptoms of Waldenström macroglobulinemia may include:

• Increased tiredness, fatigue, and reduced performance
• Pale skin or shortness of breath during exertion due to anemia
• Dizziness, headaches, or problems concentrating
• Nosebleeds or a tendency to bleed due to thrombocytopenia or hyperviscosity
• Tingling, numbness, or burning nerve pain
• Enlarged lymph nodes, spleen, or liver
• Weight loss and night sweats
• Sensitivity to cold or cryoglobulinemia

Hyperviscosity syndrome is a particularly important warning sign. In hyperviscosity syndrome, the blood becomes thicker because of high IgM levels. Symptoms can include new headaches, blurred vision, dizziness, ringing in the ears, spontaneous nosebleeds, or neurological problems. These symptoms should be checked urgently by a doctor. Hyperviscosity syndrome may need acute treatment.

It is important to know that Waldenström macroglobulinemia does not always cause symptoms right away. However, if several signs occur together or become worse over weeks, medical assessment is important. This can help detect the disease early and avoid possible complications.

The diagnosis of Waldenström macroglobulinemia usually involves several steps. These include laboratory tests, bone marrow testing, and, if needed, molecular genetic tests. Because the disease often starts slowly and causes only vague symptoms at first, the first signs are often found by chance during a blood test.

The differential blood count is especially important. In many cases, it shows anemia. Blood clotting disorders may also appear in blood tests. This is especially relevant when the raised IgM paraprotein affects blood viscosity. A clearly raised ESR is also typical in Waldenström macroglobulinemia. ESR stands for erythrocyte sedimentation rate. It can be an important sign of increased protein levels in the blood. Another central part of diagnosis is measuring immunoglobulins in the serum, especially IgG, IgA, and IgM. IgM antibodies are usually increased because the abnormal lymphoplasmacytic cells produce monoclonal IgM.

The actual diagnosis is made through a bone marrow examination. This includes a bone marrow aspirate and a bone marrow biopsy. These tests can show whether the bone marrow is infiltrated by the typical lymphoplasmacytic cells. Histological and immunohistochemical examination of the bone marrow is important. It helps confirm the disease and distinguish it from other lymphatic neoplasms.

In some cases, molecular genetic testing may also be needed. This can be useful when findings are unclear or when the disease must be distinguished from other non-Hodgkin lymphomas.

The goal of treatment for Waldenström macroglobulinemia is to relieve symptoms. Treatment also aims to prevent complications caused by the IgM paraprotein and to control the disease over time. Treatment usually begins when the first symptoms appear. It may also start when organ damaging effects occur. These can include anemia, hyperviscosity, polyneuropathy, or enlarged lymph nodes or organs.

Today, standard treatment is based on chemotherapy and Bruton tyrosine kinase inhibitors. Treatment is planned individually. It depends on age, other medical conditions, mutation status, IgM level, and symptoms.

If hyperviscosity syndrome occurs, plasmapheresis is a very important immediate measure. It quickly removes excess IgM from the blood. This can improve neurological or bleeding related complications. However, plasmapheresis does not replace the main treatment. It is combined with systemic treatment, such as chemotherapy, so that IgM production decreases in the long term.

Waldenström macroglobulinemia is now often treatable. However, it is usually not permanently curable and is considered a chronic B cell disease. Relapses are more common over time. They can often be treated again. The prognosis of Waldenström macroglobulinemia has improved significantly in recent years. Still, it depends on factors such as age at diagnosis, general health, and organ involvement. In advanced stages, the disease may lead to death because of serious complications. These include severe infections due to a weakened immune system, acute bleeding, and hyperviscosity syndrome. In this condition, increased blood viscosity can lead to organ failure or strokes.

Supportive methods are increasingly used alongside standard treatment in integrative oncology. These include complementary approaches such as acupuncture. Acupuncture aims to ease pain, nausea, sleep disorders, or inner restlessness. Targeted nutritional medical advice may also be useful. This is especially true if the disease causes deficiencies, weight loss, or treatment related symptoms.

Oncological hyperthermia may be considered as another complementary component. So far, there are no specific clinical studies for Waldenström macroglobulinemia. However, the approach is based on general findings that abnormal B cells may be sensitive to heat. At Alpine BioMedical, this procedure may be offered on individual request as supportive care. It is intended to complement standard therapies and support quality of life while living with this chronic disease.

The information listed contains relevant topics and serves to improve understanding.